Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could …

AI-Discovered Drug Shows Potential to Slow Aging in 2026 Study

A drug called rentosertib, discovered and designed entirely by artificial intelligence, has shown signs of reducing biological age markers in a small clinical trial for idiopathic pulmonary fibrosis (IPF). The biotech company Insilico Medicine reported that six independent computational aging clocks all agreed the drug lowered biological age estimates compared to placebo. While the results […]